Evaluation of a new PCR method for targeting carbapenemase-producers
Research type
Research Study
Full title
Laboratory evaluation of a new multiplex PCR for targeting carbapenemase-producing Enterobacteriaceae.
IRAS ID
210479
Contact name
John Perry
Contact email
Sponsor organisation
Newcastle upon Tyne Hospitals NHS Foundation Trust
Duration of Study in the UK
0 years, 2 months, 29 days
Research summary
Renishaw Diagnostics are currently developing a new test based on a technology known as multiplex PCR for the rapid detection of a type of antibiotic-resistant bacteria known as carbapenemase-producing Enterobacteriaceae (CPE). These bacteria cause infections in hospitalized patients and can spread rapidly in hospitals. They are extremely difficult to treat with antibiotics. The new test will enable quick detection of CPE and help us to stop them spreading in the hospital and between patients.
Screening for CPE involves testing rectal swabs from patients admitted to hospitals. Newcastle Freeman hospital is collaborating with Renishaw Diagnostics on this project and aims to help with the validation of this new test. The validation will entail creating simulated rectal swab samples that use leftover stool samples from routine diagnostic testing, and inoculating these samples with CPE bacteria. These samples will be used to validate the performance of the new test which in turn will enable Renishaw to obtain CE marking of this test before evaluating it in a clinical study.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
16/WM/0344
Date of REC Opinion
26 Jul 2016
REC opinion
Favourable Opinion